Top

World Journal of Urology

Published in:

01-02-2019 | Review

Combination of solifenacin and tamsulosin may provide additional beneficial effects for ureteral stent-related symptoms—outcomes from a network meta-analysis

Authors: Zhongyu Jian, Yuntian Chen, Qinyu Liu, Banghua Liao, Tongxin Yang, Hong Li, Kunjie Wang

Published in: World Journal of Urology | Issue 2/2019

Abstract

Purpose

To systematically evaluate the different efficacy among generally used drugs for stent-related symptoms (SRS) with the method of network meta-analysis.

Methods

A systematic search was performed in the US National Library of Medicine’s life science database (Medline), Embase, the Cochrane Central Register of Controlled Trials, and the Cochrane Database for Systematic Reviews before December 2017. Analysis was performed under multivariate random-effects network model and effects of drugs were ranked with surface under the cumulative ranking (SUCRA) probabilities.

Results

19 trials with 2036 patients investigating 4 different intervention including tamsulosin (Tam), alfuzosin (Alfu), solifenacin (Soli) and combination of Tam and Solif were finally included in our analysis. Tam plus Soli had the highest SUCRA on all aspects of ureteral stent symptom questionnaire: urinary symptoms (86.2%), body pain (85.0%), general health (80.5%), work performance (72.0%) and sexual performance (84.4%). Except for pain relief, Soli showed higher SUCRA than Tam or Alfu in rest respects. Tam and Alfu showed similar SUCRA on urinary symptoms (53.0 vs 48.7%) and body pain relief (61.9 vs 62.9%).

Conclusions

Tam plus Soli might be the most effective intervention for SRSs. As for monotherapy, Soli showed advantages in most respects except for pain relief compared to Tam or Alfu. Tam and Alfu showed similar efficacy on urinary symptoms and body pain relief.

Available only for authorised users

Zimskind PD, Fetter TR, Wilkerson JL (1967) Clinical use of long-term indwelling silicone rubber ureteral splints inserted cystoscopically. J Urol 97:840–844CrossRefPubMed

Joshi HB, Okeke A, Newns N, Keeley FX Jr, Timoney AG (2002) Characterization of urinary symptoms in patients with ureteral stents. Urology 59:511–516CrossRefPubMed

Joshi HB, Stainthorpe A, Keeley FX Jr, MacDonagh R, Timoney AG (2001) Indwelling ureteral stents: evaluation of quality of life to aid outcome analysis. J Endourol 15:151–154CrossRefPubMed

Betschart P, Zumstein V, Piller A, Schmid HP, Abt D (2017) Prevention and treatment of symptoms associated with indwelling ureteral stents: a systematic review. Int J Urol 24:250–259CrossRefPubMed

Wang J, Zhang X, Zhang T, Mu J, Bai B, Lei Y (2017) The role of solifenacin, as monotherapy or combination with tamsulosin in ureteral stent-related symptoms: a systematic review and meta-analysis. World J Urol 35:1669–1680CrossRefPubMed

Mills EJTK, Ioannidis JP (2013) Demystifying trial networks and network meta-analysis. BMJ 346:f2914CrossRef

Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700CrossRefPubMedPubMedCentral

Wiebe N, Vandermeer B, Platt RW, Klassen TP, Moher D, Barrowman NJ (2006) A systematic review identifies a lack of standardization in methods for handling missing variance data. J Clin Epidemiol 59:342–353CrossRefPubMed

Salanti G, Ades AE, Ioannidis JP (2011) Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 64:163–171CrossRef

10.

Deliveliotis C, Chrisofos M, Gougousis E, Papatsoris A, Dellis A, Varkarakis IM (2006) Is there a role for alpha 1-blockers in treating double-J stent-related symptoms? Urology 67:35–39CrossRefPubMed

11.

Damiano R, Autorino R, De Sio M, Giacobbe A, Palumbo IM, D’Armiento M (2008) Effect of tamsulosin in preventing ureteral stent-related morbidity: a prospective study. J Endourol 22:651–656CrossRefPubMed

12.

Beddingfield R, Pedro RN, Hinck B, Kreidberg C, Feia K, Monga M (2009) Alfuzosin to relieve ureteral stent discomfort: a prospective, randomized, placebo controlled study. J Urol 181:170–176CrossRefPubMed

13.

Park SC, Jung SW, Lee JW, Rim JS (2009) The effects of tolterodine extended release and alfuzosin for the treatment of double-J stent-related symptoms. J Endourol 23:1913–1917CrossRefPubMed

14.

Wang CJ, Huang SW, Chang CH (2009) Effects of specific α-1A/1D blocker on lower urinary tract symptoms due to double-J stent: a prospectively randomized study. Urol Res 37:147–152CrossRefPubMed

15.

Nazim SM, Ather MH (2012) Alpha-blockers impact stent-related symptoms: a randomized, double-blind, placebo-controlled trial. J Endourol 26:1237–1241CrossRefPubMed

16.

Lee YJ, Huang KH, Yang HJ, Chang HC, Chen J, Yang TK (2013) Solifenacin improves double-J stent-related symptoms in both genders following uncomplicated ureteroscopic lithotripsy. Urolithiasis 41:247–252CrossRefPubMed

17.

Dellis AE, Keeley FX, Manolas V, Skolarikos AA (2014) Role of α-blockers in the treatment of stent-related symptoms: a prospective randomized control study. Urology 83:56–61CrossRefPubMed

18.

Singh I, Tripathy S, Agrawal V (2014) Efficacy of tamsulosin hydrochloride in relieving “double-J ureteral stent-related morbidity”: a randomized placebo controlled clinical study. Int Urol Nephrol 46:2279–2283CrossRefPubMed

19.

Park J, Yoo C, Han DH, Shin DW (2015) A critical assessment of the effects of tamsulosin and solifenacin as monotherapies and as a combination therapy for the treatment of ureteral stent-related symptoms: a 2 × 2 factorial randomized trial. World J Urol 33:1833–1840CrossRefPubMed

20.

Abdelaal AM, Al-Adl AM, Abdelbaki SA, Al Azab MM, Al Gamal KA (2016) Efficacy and safety of tamsulosin oral-controlled absorption system, solifenacin, and combined therapy for the management of ureteric stent-related symptoms. Arab J Urol 14:115–122CrossRefPubMedPubMedCentral

21.

EL-Nahas AR, Tharwat M, Elsaadany M, Mosbah A, Gaballah MA (2016) A randomized controlled trial comparing alpha blocker (tamsulosin) and anticholinergic (solifenacin) in treatment of ureteral stent-related symptoms. World J Urol 34:963–968CrossRefPubMed

22.

Hekal IA (2016) Drug treatment of bothersome lower urinary tract symptoms after ureteric JJ-stent insertion: a contemporary, comparative, prospective, randomised placebo-controlled study, single-centre experience. Arab J Urol 14:262–268CrossRefPubMedPubMedCentral

23.

Liu Q, Liao B, Zhang R et al (2016) Combination therapy only shows short-term superiority over monotherapy on ureteral stent-related symptoms–outcome from a randomized controlled trial. BMC Urol 16:66CrossRefPubMedPubMedCentral

24.

Maldonado-Avila M, Garduño-Arteaga L, Jungfermann-Guzman R et al (2016) Efficacy of tamsulosin, oxybutynin, and their combination in the control of double-j stent-related lower urinary tract symptoms. Int Braz J Urol 42:487–493CrossRefPubMedPubMedCentral

25.

Zhang L, Li J, Pan M, Han W, Liu S, Xiao Y (2016) Doxazosin oral intake therapy to relieve stent-related urinary symptoms and pain: a prospective, randomized, controlled study. Int Braz J Urol 42:727–733CrossRefPubMedPubMedCentral

26.

Abdelhamid MH, Zayed AS, Ghoneima WE et al (2017) Randomized, double-blind, placebo-controlled trial to compare solifenacin versus trospium chloride in the relief of double-J stent-related symptoms. World J Urol 35:1261–1268CrossRefPubMed

27.

Dellis AE, Papatsoris AG, Keeley FX Jr et al (2017) Tamsulosin, solifenacin, and their combination for the treatment of stent-related symptoms: a randomized controlled study. J Endourol 31:100–109CrossRefPubMed

28.

Ragab M, Soliman MG, Tawfik A et al (2017) The role of pregabalin in relieving ureteral stent-related symptoms: a randomized controlled clinical trial. Int Urol Nephrol 49:961–966CrossRefPubMed

29.

Tanidir Y, Mangir N, Sahan A, Ulukaya M (2016) Turkish version of the ureteral stent symptoms questionnaire: linguistic and psychometric validation. World J Urol 35:1149–1154CrossRefPubMed

30.

White I (2009) Multivariate random-effects meta-analysis. Stata J 9:40–56CrossRef

31.

Lange D, Bidnur S, Hoag N, Chew BH (2015) Ureteral stent-associated complications—where we are and where we are going. Nat Rev Urol 12:17–25CrossRefPubMed

32.

Yamaguchi O (2013) Latest treatment for lower urinary tract dysfunction: therapeutic agents and mechanism of action. Int J Urol 20:28–39CrossRefPubMed

33.

Mokhtari G, Shakiba M, Ghodsi S et al (2011) Effect of terazosin on lower urinary tract symptoms and pain due to double-J stent: a double-blind placebo-controlled randomized clinical trial. Urol Int 87:19–22CrossRefPubMed

34.

Tehranchi A, Rezaei Y, Khalkhali H, Rezaei M (2013) Effects of terazosin and tolterodine on ureteral stent related symptoms: a double-blind placebo-controlled randomized clinical trial. Int Braz J Urol 39:832–840CrossRefPubMed

35.

Kuyumcuoglu U, Eryildirim B, Tuncer M, Tarhan F, Ozgül A (2012) Effectiveness of medical treatment in overcoming the ureteral double-J stent related symptoms. Can Urol Assoc J 6:E234–E237CrossRefPubMed

Title: Combination of solifenacin and tamsulosin may provide additional beneficial effects for ureteral stent-related symptoms—outcomes from a network meta-analysis
Authors: Zhongyu Jian
Yuntian Chen
Qinyu Liu
Banghua Liao
Tongxin Yang
Hong Li
Kunjie Wang
Publication date: 01-02-2019
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 2/2019
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-018-2404-6

ACC 2024 Congress

Springer Medicine

Combination of solifenacin and tamsulosin may provide additional beneficial effects for ureteral stent-related symptoms—outcomes from a network meta-analysis

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2019

Do patients have to choose between ejaculation and miction? A systematic review about ejaculation preservation technics for benign prostatic obstruction surgical treatment

Comparison between the effects of deep and moderate neuromuscular blockade during transurethral resection of bladder tumor on endoscopic surgical condition and recovery profile: a prospective, randomized, and controlled trial

Extra-target low-risk prostate cancer: implications for focal high-intensity focused ultrasound of clinically significant prostate cancer

Endoscopic intact removal of medium-size- or multiple bladder stones with the use of transvesical laparoendoscopic single-site surgery

Controversies in MR targeted biopsy: alone or combined, cognitive versus software-based fusion, transrectal versus transperineal approach?

The value of periprostatic fascia thickness and fascia preservation as prognostic factors of erectile function after nerve-sparing robot-assisted radical prostatectomy